"No surprises" in first half for AOI after R&D (research and development) widens net loss
This article was originally published in Clinica
Orlando, Florida-based orthopaedics specialist AOI Medical has stated that "everything is according to plan", despite seeing its net loss widen to $1.8m for the six months ending June 30 2007. The firm doubled its net loss to reflect its rising operating expenses - a result of a five-fold increase in R&D spending to $577,000, and administrative costs nearly doubling to $1m. During this period, the company also invested in expanding its workforce, and sales and marketing activities.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.